A US-based firm is investing from a multi-million dollar evergreen fund and is interested in a variety of sectors including the life science field. For life science investments, the firm typically allocates $2-15 million, and prefers to invest in Series B-C rounds. The firm invests primarily in the USA and Canada.
The firm is presently focused on technologies that involve an IT/software component, across digital health, healthcare services, medtech, and diagnostics. The firm is open to opportunities in any clinical indication, especially ocular. The firm is only interested in devices and diagnostics that have in-human data, have received marketing approval and are in the commercialization stage.
In the life science sector, the firm is not interested in early-stage R&D opportunities; howeverthe firm is open to both companies with an approved product on the market, and companies with a product in late-stage clinical trials. The firm takes the strength of the management team into consideration.
If you are interested in more information about this investor and other investors tracked by LSN, please email firstname.lastname@example.org